Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | RCC data at ESMO 2020

Laurence Albiges • 18 Sep 2020
ESMO 2020
Genitourinary Cancer Kidney Cancer Cabozantinib Nivolumab Sunitinib
CheckMate 9ER

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, highlights the important studies being reported at the ESMO 2020 virtual meeting. Dr Albiges highlights the CheckMate 9ER clinical trial (NCT03141177) as one to look out for. This phase III study compared nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma (RCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Laurence Albiges

LITESPARK-005: Belzutifan versus everolimus in ccRCC
2:48
LITESPARK-005: Belzutifan versus everolimus in ccRCC
Laurence Albiges • 21 Oct 2023
Biomarker development in RCC and UC
4:21
Biomarker development in RCC and UC
Laurence Albiges • 23 Sep 2021
Current and emerging treatment strategies for patients with mccRCC
2:24
Current and emerging treatment strategies for patients with mccRCC
Laurence Albiges • 23 Sep 2021
BIONIKK: the first trial study in mccRCC
1:50
BIONIKK: the first trial study in mccRCC
Laurence Albiges • 18 Sep 2020

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals